CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 460 enrolled
Drug / intervention
Non-Interventional +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05510908
NCT05510908N/ACompleted

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium A Trial of the AIDS Malignancy Consortium (AMC)

AIDS Malignancy Consortium·observational·Posted Aug 22, 2022·Updated Mar 25, 2026

In Brief

An observational study evaluating Non-Interventional and Non-Interventional Follow-up for HIV-Associated Malignant Neoplasm and 7 related conditions. Completed, enrolled 460 participants across 16 sites in 2 countries.

Detailed Summary

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States

Timeline

N/ACompletedFinished
2023202420252026
First PostedAug 22, 2022
Enrollment StartJul 25, 2023
Primary CompletionFeb 28, 2025
Study CompletionJun 2, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.9 years ago

Interventions

Non-Interventionalother

Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Non-Interventional Follow-upother

Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.